Literature DB >> 1815390

Molecular mechanisms of cancer.

H P Koeffler1, F McCormick, C Denny.   

Abstract

Cancer is caused by specific DNA damage. Several common mechanisms that cause DNA damage result in specific malignant disorders: First, proto-oncogenes can be activated by translocations. For example, translocation of the c-myc proto-oncogene from chromosome 8 to one of the immunoglobulin loci on chromosomes 2, 14, or 22 results in Burkitt's lymphomas. Translocation of the c-abl proto-oncogene from chromosome 9 to the BCR gene located on chromosome 22 produces a hybrid BCR/ABL protein resulting in chronic myelogenous leukemia. Second, proto-oncogenes can be activated by point mutations. For example, point mutations of genes coding for guanosine triphosphate-binding proteins, such as H-, K-, or N-ras or G proteins, can be oncogenic as noted in a large variety of malignant neoplasms. Proteins from these mutated genes are constitutively active rather than being faithful second messengers of periodic extracellular signals. Third, mutations that inactivate a gene can result in tumors if the product of the gene normally constrains cellular proliferation. Functional loss of these "tumor suppressor genes" is found in many tumors such as colon and lung cancers. The diagnosis, classification, and treatment of cancers will be greatly enhanced by understanding their abnormalities at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815390      PMCID: PMC1003063     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  125 in total

1.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence.

Authors:  F J Rauscher; J F Morris; O E Tournay; D M Cook; T Curran
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

2.  Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer.

Authors:  S L Naylor; B E Johnson; J D Minna; A Y Sakaguchi
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

3.  Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung.

Authors:  H Brauch; B Johnson; J Hovis; T Yano; A Gazdar; O S Pettengill; S Graziano; G D Sorenson; B J Poiesz; J Minna
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

4.  Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt.

Authors:  C M Croce; W Thierfelder; J Erikson; K Nishikura; J Finan; G M Lenoir; P C Nowell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

5.  Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.

Authors:  T H Rabbitts; P H Hamlyn; R Baer
Journal:  Nature       Date:  1983 Dec 22-1984 Jan 4       Impact factor: 49.962

6.  Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cells.

Authors:  R Taub; C Moulding; J Battey; W Murphy; T Vasicek; G M Lenoir; P Leder
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

7.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.

Authors:  G Grosveld; T Verwoerd; T van Agthoven; A de Klein; K L Ramachandran; N Heisterkamp; K Stam; J Groffen
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

8.  Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers.

Authors:  K W Kinzler; M C Nilbert; B Vogelstein; T M Bryan; D B Levy; K J Smith; A C Preisinger; S R Hamilton; P Hedge; A Markham
Journal:  Science       Date:  1991-03-15       Impact factor: 47.728

9.  Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors:  N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

10.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

Authors:  J B Konopka; S M Watanabe; O N Witte
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

View more
  10 in total

1.  Molecular genetics in the cancer clinic.

Authors:  E H Radany
Journal:  West J Med       Date:  1991-11

2.  Acquisition of telomere repeat sequences by transfected DNA integrated at the site of a chromosome break.

Authors:  J P Murnane; L C Yu
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

Review 3.  Roles for KRAS in pancreatic tumor development and progression.

Authors:  Marina Pasca di Magliano; Craig D Logsdon
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

4.  Oncogenic K-Ras requires activation for enhanced activity.

Authors:  H Huang; J Daniluk; Y Liu; J Chu; Z Li; B Ji; C D Logsdon
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

5.  K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer.

Authors:  M Sagawa; Y Saito; S Fujimura; R I Linnoila
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 6.  Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development.

Authors:  Jeong-Ryul Hwang; Yeongseon Byeon; Donghwan Kim; Sung-Gyoo Park
Journal:  Exp Mol Med       Date:  2020-05-21       Impact factor: 8.718

Review 7.  Nicotinamide adenine dinucleotide and the sirtuins caution: Pro-cancer functions.

Authors:  Raymond D Palmer; Mauro Vaccarezza
Journal:  Aging Med (Milton)       Date:  2021-11-30

Review 8.  Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.

Authors:  Mario Morales-Martínez; Mario I Vega
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

Review 9.  Amplification of Cellular Oncogenes in Solid Tumors.

Authors:  Ozkan Bagci; Serkan Kurtgöz
Journal:  N Am J Med Sci       Date:  2015-08

10.  Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.

Authors:  Sara Alves; Lisandra Castro; Maria Sofia Fernandes; Rita Francisco; Paula Castro; Muriel Priault; Susana Rodrigues Chaves; Mary Pat Moyer; Carla Oliveira; Raquel Seruca; Manuela Côrte-Real; Maria João Sousa; Ana Preto
Journal:  Oncotarget       Date:  2015-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.